Login / Signup

Heterogeneous HER2 Amplification-a New Clinical Category of HER2-Positive Breast Cancer?

Alicia F C OkinesNicholas C Turner
Published in: Cancer discovery (2022)
HER2 amplification heterogeneity is associated with resistance to trastuzumab emtansine in the neoadjuvant setting, emphasizing the importance of assessing whether heterogeneous HER2-positive cancers require different treatment pathways. See related article by Metzger Filho et al., p. 2474 .
Keyphrases
  • positive breast cancer
  • nucleic acid
  • metastatic breast cancer
  • rectal cancer
  • lymph node
  • single cell
  • epidermal growth factor receptor
  • drug induced